Treatment of chronic hepatitis C in elderly patients

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 4, 2010, Pages 571-577

  Horsmans, Y ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Chronic hepatitis C; Co morbidities; Elderly; Life expectancy; Pegylated interferon; Ribavirin; Side effects

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN;

AGED; ANTIVIRAL THERAPY; APPETITE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DERMATITIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE EXPECTANCY; LIVER CANCER; LIVER FAILURE; LIVER FIBROSIS; NEUTROPENIA; PREVALENCE; QUALITY OF LIFE; RETINA HEMORRHAGE; REVIEW; SIDE EFFECT; VIRUS CARCINOGENESIS;

AGE FACTORS; AGED; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; LIFE EXPECTANCY; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77249096028     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903468710     Document Type: Review

References (48)

1. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial tretament of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al.; PEGASYS international study group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
4. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14
5. McHutchinson JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005;11:S286-95
6. Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997;26:1006-11
7. Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 2005;75:522-7
8. Gordon SC, Elloway RS, Long JC, et al. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 1993;18:1338-43
9. Yano M, Yatsuhashi H, Inoue O, et al. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut 1993;34:S13-16
10. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32
11. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009;29:(Suppl 1):89-99
12. Floreani A, Bertin T, Soffiati G, et al. Anti-hepatitis C virus in the elderly: a seroepidemiological study in a home for the aged. Gerontology 1992;38:214-6
13. Solana R, Pawelec G. molecular and cellular basis of immunosenescence. Mech Ageing Dev 1998;102:115-29
14. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004;5:133-9
15. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009;119:1745-54
16. Hoare M, Gelson W, Das A, et al. Immune senescence, independent of age, informs the clinical outcome of chronic hepatitis C virus (HCV) infection. Hepatology 2008;48(Suppl):780-1A
17. Fargnoli J, Kunisada T, Fornace AJ, et al. Decreased expression of heat shock protein 70mRNA and protein after heat treatment in cells of aged rats. Proc Natl Acad Sci USA 1990;87:846-50
18. Zhang HJ, Doctrow SR, Oberley LW, et al. Chronic antioxidant enzyme mimetic treatment differentially modulates hyperthermia-induced liver HSP70 expression with aging. J Appl Physiol 2006;100:1385-91
19. Ratziu V, Dargere D, Conti M, et al. Increased fibrotic response in the aging liver. Hepatology 2000;32:302A
20. Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008;134:657-67
21. Bresci G, Del Corso L, Romanelli AM, et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc 1993;41:857-62
22. Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival exhibiting a biochemical response. J Gastroenterol 2004;39:1069-77
23. Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995;10:246-9
24. Alessi N, Freni MA, Spadaro A, et al. Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med 2003;11:208-12
25. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007;50:16-23
26. Ikeda K, Arase Y, Kawamura Y, et al. Necessities of interferon therapy in elderly patients with chronic hepatitis C. Am J Med 2009;122:479-86
27. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006;101:1260-7
28. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2005;43:54-63
29. Hiramatsu N, Oze T, Tsuda N, et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 2006;35:185-9
30. Koyama R, Arase Y, Ikeda K, et al. Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2006;49:121-6
31. Kumada T, Toyoda H, Honda T, et al. Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. Intervirology 2006;49:112-8
32. Honda T, Katano Y, Urano F, et al. Efficacy of ribavirin plus interferon-alpha in patients aged > 60 years with chronic hepatitis C. J Gastroenterol Hepatol 2007;22:989-95
33. Floreani A, Monola E, Carderi I, et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J Am Geriatr Soc 2006;54:549-50
34. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007;102:1383-91
35. Puoti M, Minola E, Antonini MG, et al. Older age is associated with an impaired response to combination pegylated interferon and ribavirin treatment for chronic hepatitis C in a case control study. J Hepatol 2008;48:S309
36. Dai CY, Huang CF, Yu ML, et al. Efficacy and safety of pegylated interferon-alpha plus ribavirin combination therapy in old age chronic hepatitis C patients. J Hepatol 2009;50:S227
37. Sezaki H, Suzuki F, Kawamura Y, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009;54:1317-24
38. Honda T, Katano Y, Shimuzu J, et al. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 2009. [Epub ahead of print]
39. Reddy KJ, Messinger D, Popescu M, et al. Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat 2009;16:724-31
40. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999;131:174-81
41. Asahina Y, Izuni N, Hirayama I, et al. Potential negative impact of aging on hepatocarcinogenesis after anti-viral treatment in patients with chronic hepatitis C and benefit of viral eradication by peg-interferon/ribavirin treatment. J Hepatol 2008;48:S7
42. Veldt BJ, Heathcote J, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84
43. Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37
44. Gerkens S, Nechelput M, Annemans L, et al. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2-a and ribavirin in patients withy mild chronic hepatitis C. J Viral Hepat 2007;14:523-36
45. Gerkens S, Nechelput M, Annemans L, et al. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2-a and ribavirin with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg 2007;70:177-87
46. Neumann AU, Pianko S, Zeuzem S, et al. Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C. J Hepatol 2009;51:21-8
47. Martinot-Peignoux M, Maylin S, Moucari R, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther 2009;14:501-11
48. Thompson AJ, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009;16:377-87